Abvc Biopharma (ABVC) EBT (2010 - 2026)

Abvc Biopharma (ABVC) has reported EBT for 16 consecutive years, with -$810481.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 64.9% year-over-year to -$810481.0; the trailing twelve-month figure through Jun 2026 stood at -$7.6 million (down 67.51% YoY), and the FY2025 full-year result was -$8.4 million, down 55.56% from the prior year.
• EBT advanced to -$810481.0 in Q2 2026 per ABVC's latest filing, from -$1.7 million in the prior quarter.
• Across five years, EBT topped out at -$487076.0 in Q3 2024 and bottomed at -$6.2 million in Q1 2022.
• Historically, EBT has averaged -$2.2 million across 5 years, with a median of -$2.1 million in 2022.
• The sharpest annual moves came in 2022 and 2024: EBT plunged 395.41% in 2022, then jumped 85.54% in 2024.
• Over 5 years, EBT stood at -$3.5 million in 2022, then surged by 85.16% to -$524999.0 in 2023, then plunged by 51.72% to -$796527.0 in 2024, then slumped by 278.7% to -$3.0 million in 2025, then soared by 73.13% to -$810481.0 in 2026.
• According to Business Quant data, EBT over the past three periods registered -$810481.0, -$1.7 million, and -$3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.